91 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of benzofuran-3(2H)-one derivatives as novel DRAK2 inhibitors that protect islet?-cells from apoptosis.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
East China Normal University
Discovery of Potent and Selective Inhibitors of Cdc2-Like Kinase 1 (CLK1) as a New Class of Autophagy Inducers.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Sichuan University and Collaborative Innovation Center For Biotherapy
Synthesis and optimization of furano[3,2-d]pyrimidines as selective spleen tyrosine kinase (Syk) inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Abbvie Bioresearch Center
Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Nebraska Medical Center
Discovery of a Potent, Selective, Orally Bioavailable, and Efficacious Novel 2-(Pyrazol-4-ylamino)-pyrimidine Inhibitor of the Insulin-like Growth Factor-1 Receptor (IGF-1R).![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Astrazeneca
5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Palack£
Rational design of inhibitors of the bacterial cell wall synthetic enzyme GlmU using virtual screening and lead-hopping.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Astrazeneca
10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Technische Universit£T Braunschweig
Design, synthesis and biological evaluation of novel aminothiazoles as antiviral compounds acting against human rhinovirus.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Boehringer Ingelheim (Canada)
Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Oxford
Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Cellzome
Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) for the treatment of rheumatoid arth![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
S Bio
Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Abbott Laboratories
A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Nerviano Medical Sciences Oncology
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Oxford
Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and preliminary pharmacokinetics.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Abbott Laboratories
Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
The Institute of Cancer Research
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Ambit Biosciences
Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Cyclacel
A diaminocyclohexyl analog of SNS-032 with improved permeability and bioavailability properties.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Sunesis Pharmaceuticals
Cell division cycle 7 kinase inhibitors: 1H-pyrrolo[2,3-b]pyridines, synthesis and structure-activity relationships.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Nerviano Medical Sciences
From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Illinois At Chicago
Modifications of the isonipecotic acid fragment of SNS-032: analogs with improved permeability and lower efflux ratio.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Sunesis Pharmaceuticals
Natural Product-Inspired Targeted Protein Degraders: Advances and Perspectives.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Tongji University School of Medicine
Identification of potent 5-pyrimidinyl-2-aminothiazole CDK4, 6 inhibitors with significant selectivity over CDK1, 2, 5, 7, and 9.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Banyu Tsukuba Research Institute
Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Hefei University of Technology
Kinase Inhibitors as Underexplored Antiviral Agents.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Centro De Investigaciones Biol�Gicas Margarita Salas (Csic)
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Csir-Indian Institute of Integrative Medicine
Current progress and novel strategies that target CDK12 for drug discovery.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
West China Hospital
Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target Engagement.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Astrazeneca
Development and Therapeutic Potential of NUAKs Inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Science and Technology (Ust)
Structure-Guided Discovery of Potent and Selective DYRK1A Inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Servier Research Institute of Medicinal Chemistry
Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Bayer Pharma
Fragment-Derived Selective Inhibitors of Dual-Specificity Kinases DYRK1A and DYRK1B.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Vernalis (R&D)
Discovery of thiazolidin-4-one analogue as selective GSK-3? inhibitor through structure based virtual screening.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Central University of Rajasthan
Rational Design and Development of Novel CDK9 Inhibitors for the Treatment of Acute Myeloid Leukemia.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Chinese Academy of Sciences
Balancing Properties with Carboxylates: A Lead Optimization Campaign for Selective and Orally Active CDK9 Inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Abbvie
Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Nebraska Medical Center
Discovery of a novel covalent CDK4/6 inhibitor based on palbociclib scaffold.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Sichuan University
Identification of a new series of flavopiridol-like structures as kinase inhibitors with high cytotoxic potency.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University Paris-Saclay
Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Shanghaitech University
Rational Design and Evaluation of 6-(Pyrimidin-2-ylamino)-3,4-dihydroquinoxalin-2(1![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Chinese Academy of Sciences
Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
China Pharmaceutical University
2-Arylamino-6-ethynylpurines are cysteine-targeting irreversible inhibitors of Nek2 kinase.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Newcastle University
Discovery of potent glycogen synthase kinase 3/cholinesterase inhibitors with neuroprotection as potential therapeutic agent for Alzheimer's disease.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
China Pharmaceutical University
Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Astrazeneca
Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
The First Affiliated Hospital of Zhengzhou University
CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Lebanese American University
Discovery and Pharmacokinetic and Pharmacological Properties of the Potent and Selective MET Kinase Inhibitor 1-{6-[6-(4-Fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylsulfanyl]benzothiazol-2-yl}-3-(2-morpholin-4-ylethyl)urea (SAR125844).![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Sanofi-Aventis Germany
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019).![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Eli Lilly
Recent advances in the development of cyclin-dependent kinase 7 inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Tianjin University of Science and Technology
A review on flavones targeting serine/threonine protein kinases for potential anticancer drugs.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
China Pharmaceutical University
Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Padova
Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of South Australia Cancer Research Institute
Kinase Chemodiversity from the Arctic: The Breitfussins.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Uit - The Arctic University of Norway
Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Eppley Institute For Research In Cancer and Allied Diseases
Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Astrazeneca
Discovery of a Selective and Potent Inhibitor of Mitogen-Activated Protein Kinase-Interacting Kinases 1 and 2 (MNK1/2) Utilizing Structure-Based Drug Design.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Novartis Institutes For Biomedical Research
Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Central University of Punjab
Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Seoul National University
Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Chinese Academy of Sciences
Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy?![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of South Australia
Discovery and synthesis of novel Wogonin derivatives with potent antitumor activity in vitro.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
China Pharmaceutical University
Design, synthesis and biological evaluation of pyrimidine derivatives as novel CDK2 inhibitors that induce apoptosis and cell cycle arrest in breast cancer cells.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Shihezi University
Discovery of N-substituted 7-azaindoles as PIM1 kinase inhibitors - Part I.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Sanofi Genzyme
Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Genentech
Design and synthesis of selective CDK8/19 dual inhibitors: Discovery of 4,5-dihydrothieno[3',4':3,4]benzo[1,2-d]isothiazole derivatives.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Takeda Pharmaceutical
A patent review on SARS coronavirus main protease (3CLpro) inhibitors.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Experimental Drug Development Centre
Synthetic and Crystallographic Studies of a New Inhibitor Series Targeting Bacillus anthracis Dihydrofolate Reductase.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
University of Connecticut